Form 4: Caris Life Sciences Director Halbert Boosts Stake

Caris Life Sciences Director Jon Halbert acquired additional common stock as part of his 2025 board retainer compensation.

Summary

• Jon Halbert, a Director of Caris Life Sciences, Inc., acquired 2,492 shares of common stock on February 26, 2026.
• The shares were issued in lieu of cash compensation for his 2025 board retainer fees.
• The share price for this transaction was $20.06 per share, determined by the ten trading day average of the daily volume weighted average price through February 25, 2026.
• Following this transaction, Jon Halbert directly beneficially owns 118,621 shares of common stock.
• Additionally, 1,250,000 shares previously held indirectly by Ke'Ohana Ventures, LLC were distributed in kind to its members, with 625,000 shares going to the Jon and Linda Halbert Management Trust and 625,000 shares to LAH Investments, Ltd.
• Jon Halbert indirectly beneficially owns 625,000 shares through LAH Investments, Ltd. and 625,000 shares through the Family Trust, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive disclosure. While the share acquisition is for compensation, it increases a director's direct stake, signaling continued alignment with shareholder interests. The re-distribution of indirect holdings is an administrative change.

Positives

• Director Jon Halbert increased his direct beneficial ownership in Caris Life Sciences, Inc. by 2,492 shares, aligning his interests further with shareholders.
• The issuance of shares in lieu of cash compensation for board retainer fees can be viewed as a positive for the company's cash flow management.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions, are often viewed by the market as a signal of management's confidence in the company's future prospects. While this specific acquisition is for compensation, it still represents an increase in direct ownership by a director, which can be a positive indicator for investors in the life sciences sector.

Comparison to Industry Standards

• StockSavvy.ai observes that receiving equity as part of board compensation is a common practice across various industries, including life sciences, aligning director incentives with shareholder value. For instance, many biotech and pharmaceutical companies, such as Amgen or Gilead Sciences, frequently compensate their non-employee directors with restricted stock units or stock options.
• The method of determining share price based on a volume-weighted average price (VWAP) over a period is a standard and transparent approach for non-cash compensation, similar to practices seen in companies like Illumina or Thermo Fisher Scientific when issuing equity awards.

Related Party Transactions

• The distribution of 1,250,000 shares from Ke'Ohana Ventures, LLC to the Jon and Linda Halbert Management Trust (Family Trust) and LAH Investments, Ltd. represents a related party transaction involving entities associated with the reporting person.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a director may be perceived positively, indicating management's continued commitment and belief in the company's value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Caris Life Sciences, CAI, Jon Halbert, Director, Insider Transaction, Form 4, Stock Acquisition, Board Compensation, Beneficial Ownership